Gilead Sciences: Here’s What Investors Need to Know Before Earnings
Gilead Sciences (NASDAQ:GILD) will report earnings after markets close on Thursday, July 25th. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
Here is your Cheat Sheet to Gilead Sciences Earnings:
Earnings Expectations: Analysts expect earnings of $0.50 per share on revenues of $2.66 billion. Currently, the company’s P/E ratio stands at 32.60.
Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.49 and has not changed. For the current year, the average estimate is a profit of $1.98, which is worse than the estimate ninety days ago.
Here’s how Gilead Sciences has been performing on an annual basis:
|Revenue ($) in millions||5,336||7,011||7,949||8,385||9,703|
|Diluted EPS ($)||1.05||1.41||1.66||1.77||1.64|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||2,405.19||2,426.60||2,588.28||2,531.64|
|Diluted EPS ($)||0.46||0.43||0.47||0.43|
Gilead Sciences has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)